
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 2.690 | 2.690 | 0.000 |
Shares | 97.300 | 97.300 | 0.000 |
Other | 0.010 | 0.010 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 24.962 | 18.667 |
Price to Book | 7.558 | 3.188 |
Price to Sales | 5.543 | 2.329 |
Price to Cash Flow | 20.260 | 12.639 |
Dividend Yield | 1.132 | 2.018 |
5 Years Earnings Growth | 9.939 | 10.533 |
Name | Net % | Category Average |
---|---|---|
Technology | 43.000 | 20.028 |
Healthcare | 37.030 | 12.988 |
Communication Services | 19.970 | 9.671 |
Number of long holdings: 37
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Alphabet A | US02079K3059 | 8.91 | 171.74 | -0.07% | |
Apple | US0378331005 | 8.46 | 200.85 | +0.45% | |
NVIDIA | US67066G1040 | 7.32 | 135.13 | -2.92% | |
Microsoft | US5949181045 | 7.11 | 460.36 | +0.37% | |
Meta Platforms | US30303M1027 | 6.56 | 647.49 | +0.38% | |
Eli Lilly | US5324571083 | 5.25 | 737.67 | +2.09% | |
Roche Holding Participation | CH0012032048 | 4.77 | 266.80 | +0.49% | |
UnitedHealth | US91324P1021 | 4.62 | 301.91 | +1.25% | |
Novartis | CH0012005267 | 4.13 | 95.56 | +1.63% | |
Thermo Fisher Scientific | US8835561023 | 3.84 | 402.82 | -0.23% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Renaissance Global Growth | 4.86B | -6.08 | 8.13 | 8.65 | ||
Renaissance Global Growth Class F | 4.86B | -5.68 | 9.53 | 10.07 | ||
Renaissance International Equity | 1.83B | -1.08 | 5.27 | 5.44 | ||
Renaissance International Equity Cl | 1.83B | -0.66 | 6.63 | 6.86 | ||
Renaissance US Equity Income F | 1.46B | -4.00 | 7.04 | 9.24 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review